strong operational performance+-+-Pfizer forecast revenue+-+-York-based Pfizer Inc.+-+-Pfizer shares+-+-premarket trading+-+-net income+-+-Wall Street expectations+-+-biggest U.S. drugmaker+-+-percent+-+-fellow drugmaker Allergan+-+-first-quarter net income+-+-Zacks Investment Research+-+-pain treatment Lyrica+-+-cents+-+-lower-cost biotech drugs+-+-currency exchange rates+-+-infusion device maker+-+-legacy Hospira operations+-+-Hospira cost savings+-+-initial cost savings+-+-injectable drugmaker+-+-latest quarter+-+-higher sales+-+-injectable drugs+-+-lower tax+-+-financial forecasts+-+-business outlook+-+-one-time items+-+-prior forecast+-+-global market+-+-new class+-+-Established businesses+-+-key driver+-+-excellent progress+-+-Ian Read+-+-chief executive+-+-earnings-per-share guidance+-+-analysts+-+-deal+-+-range+-+-Viagra+-+-remainder+-+-company+-+-record+-+-headquarters+-+-paper+-+-Ireland+-+-taxes+-+-period+-+-chairman+-+-changes+-+-purchase+-+-biosimilars+-+-Standard+-+-index+-+-board+-+-statement+-+-Tuesday+-+-Plc+-+-lift+-+-profit